Genetic analysis predicted varespladib's failure in VISTA-16

Results from a Mendelian randomization meta-analysis of 19 general population studies and ten acute coronary syndrome cohorts suggested varespladib was unlikely to reduce the risk of recurrent cardiovascular events.

Source: theHeart.org - August 19, 2013 Category: Cardiology Source Type: news